WELCOME TO VIRTUAL DISCOVERY
A Galaxy of Small Molecule Drugs Awaits
ABOUT US
At Virtual Discovery, we have a vision of a world in which every disease can be cured.
Our mission is to help pharmaceutical companies discover new therapeutics using technologies that are dramatically faster and cheaper than traditional wet-lab methods
OUR TECHNOLOGY
We use VirtualFlow (Nature 2020) to carry out the largest virtual screenings in the world. We are able to screen against a variety of compound libraries—including the REAL library by Enamine, which contains more than 1.2 billion compounds.
WHAT WE OFFER
HIT IDENTIFICATION
We discover potent hit and lead compounds using ultra-large virtual screenings (on the order of billions of small molecules)
LEAD IDENTIFICATION
We optimize hit and lead compounds by screening hundreds of thousands of analogs against a particular target
WHY VIRTUAL DISCOVERY?
HIGHLY EFFECTIVE
Since we can explore the chemical space far more thoroughly than traditional methods, our hits are usually better in terms of binding affinity and other ADMET related properties
QUICK
We can screen billions of compounds in a matter of days.
INEXPENSIVE
Screening in silico is dramatically cheaper than traditional wet-lab-based methods like HTS
WHO WE ARE
DR. GERHARD WAGNER, FOUNDER
Dr. Gerhard Wagner, Elkan Blout Professor of Biological Chemistry and Molecular Pharmacology, Biological Chemistry and Molecular Pharmacology, Harvard Medical School, is an elected fellow of the American Association for the Advancement of Science, German National Academy, American Academy of Arts and Sciences, National Academy of Science, and International Society of Magnetic Resonance. Dr. Wagner is experienced in computational drug discovery, and he supervises the VirtualFlow project. His work includes identifying small-molecule inhibitors of protein-protein interaction and their potential uses as anti-cancer agents.